FindTrial
Sign In

LCL161

DRUG9 trials

Sponsors

Novartis Pharmaceuticals, US Oncology Research, SCRI Development Innovations, LLC, Novartis

Conditions

Advanced Solid TumorsBreast CancerColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell CarcinomaMetastatic Pancreatic CancerMultiple MyelomaNeoplasmsOvarian CancerSmall Cell Lung Cancer

Phase 1

Safety and Efficacy of LCL161 in Patients With Solid Tumors
CompletedNCT01098838
Novartis PharmaceuticalsAdvanced Solid Tumors
Start: 2008-11-30End: 2011-01-31Updated: 2012-08-03
A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors
CompletedNCT01240655
Novartis PharmaceuticalsSolid Tumors
Start: 2011-04-30End: 2015-01-31Updated: 2020-12-19
Phase I Trial of LCL161 and Gemcitabine Plus Nab-Paclitaxel in Metastatic Pancreatic Cancer
NCT01934634
US Oncology ResearchMetastatic Pancreatic Cancer
Start: 2014-03-31Target: 24Updated: 2015-11-10
Safety and Tolerability of Oral LCL161 in Japanese Adult Patients With Advanced Solid Tumors
CompletedNCT01968915
Novartis PharmaceuticalsNeoplasms
Start: 2013-11-30End: 2015-06-30Updated: 2020-12-19
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
TerminatedNCT02649673
SCRI Development Innovations, LLCOvarian Cancer, Small Cell Lung Cancer
Start: 2016-03-23End: 2021-07-30Updated: 2023-12-05
A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
CompletedNCT02890069
Novartis PharmaceuticalsColorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
Start: 2016-10-14End: 2022-02-22Updated: 2023-01-11
Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma
CompletedNCT03111992
Novartis PharmaceuticalsMultiple Myeloma
Start: 2017-12-18End: 2020-03-02Updated: 2022-02-09

Phase 2

A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
CompletedNCT01617668
Novartis PharmaceuticalsBreast Cancer
Start: 2012-08-31End: 2014-09-30Updated: 2016-10-17

Unknown Phase

Phase Ib, open-label, multi-center study to characterize the safety, tolerability and pharmacodynamics (PD) of PDR001 in combination with LCL161, everolimus (RAD001) or panobinostat (LBH589) (CPDR001X2102)
Active, not recruitingNL-OMON47909
Novartiscolorectaal kanker (muv mismatch repair deficienties), non-small cell long kanker (adenocarcinoma) en triple negatieve borstkanker and breast cancer non-familial colorectal cancer NSCLC RCC
Start: 2016-10-14Target: 43Updated: 2024-02-28

Related Papers

Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells
Cancer Cell International2024-05-243 citations
A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
The Oncologist2023-05-0210 citations
A phase II, open-label, neoadjuvant, randomized study of LCL161 with paclitaxel in patients with triple-negative breast cancer (TNBC).
Journal of Clinical Oncology2015-05-2013 citations
Abstract OT1-4-04: A phase II randomized, open-label, neoadjuvant study of LCL161, an oral antagonist of inhibitor of apoptosis proteins, in combination with paclitaxel in patients with triple-negative breast cancer
Cancer Research2013-12-15